Synaptic sound

Decibel Therapeutics Inc. plans to use new mechanistic insights by its academic founders to develop therapies that protect against, restore or repair hearing loss. The company is armed with a $52 million series A round to amass what it expects will be the industry's broadest hearing loss portfolio.

The basis for Decibel's formation is a critical mass of publications in the past five years that showed many hearing disorders were caused by defects in the synapse between inner ear hair cells and auditory nerve fibers, rather than defects in the hair cells or nerves themselves. ...